Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemoembolic agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent, and for 30 days after discontinuation of therapy
Pregnant women are excluded from this study; breastfeeding must be discontinued while the mother is taking study drug and for at least 28 days after discontinuation of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for the duration of study participation and for 56 days after the last dose of the study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30